Notice of Launching Anti AGE-3 Monoclonal
Antibody
|
|
|
| |
|
We hereby announce that TRANS GENIC INC. (hereinafter
referred to as q�weq�) have released anti AGE-3 monoclonal antibody
(hereinafter referred to as q㏄he antibodyq�) developed by GANP®Mouse
Technology (*1) on September 27, 2007.
|
|
It has been suggested that AGEs (Advanced Glycation End Products)
(*2) are closely linked to diabetes-related diseases and chronic
disorders caused by aging. We have distributed many AGEs-related
antibodies (eight monoclonal antibodies and two polyclonal antibodies)
and they have become leading products in our antibody reagent
business.
AGE-3 (*3) among other AGEs is considered to be particularly
related to development and progression of various diseases such
as diabetic complications (e.g. diabetic retinopathy and nephropathy).
We have successfully developed the antibody by administering
artificially produced AGE-3 to genetically engineered q⑧ANP®miceq� and selecting antibody-producing cell lines which show
high-specificity against AGE-3.
q_q_The following is the summery of the launch of the antibody.
Product Name |
Anti AGE-3 Monoclonal Antibody
Clone No.9D8 (Code KG122) |
Quantity |
10 μg |
Price |
57,750 yen (consumption tax
included) |
Distribution method |
The antibody is sold through
our distributing agents
Cosmo Bio Co., Ltd.,
Funakoshi Corporation,
Wako Pure Chemical Industries, Ltd.
|
Annual Sales Prospect |
50 - 100 units |
Besides developing diagnostic reagents, we are distributing
antibodies as research reagents to support advancement of life-science
such as researches on proteins and identification of causes of
various diseases. We will continuously make our efforts to develop
new antibody reagents utilizing our unique GANP®Mouse Technology
(*1) and DNA immunization (*4) in order to enhance our product
lineups in the area of cancer and metabolic syndrome.
The effects of the launch of the antibody on our business
performance are as yet unknown, but we will make an announcement
as soon as it is revealed to have a significant impact on our future
performance.
q_q_Reference:Overview of business using GANP®Mouse
Technology (*1)
qﾎ.
Commercialization
|
1-1 |
Number of research
reagents launched: 3
|
| |
|
- Anti GPR40 antibody: launched on April 27,
2007
- Anti HIV (gp120) antibody: launched on September 5, 2007
- Anti AGE-3 antibody: launched on September 27, 2007 |
1-2 |
Number of licensing we have granted
for developing diagnostic reagents: 3 |
| |
| qﾏ. Number of custom
production service of antibodies: 62 |
| |
|
Note:
|
|
*1 |
GANP®Mouse Technology
This is our unique technology to produce antibodies using q⑧ANP® miceq�,
genetically engineered mice whose GANP gene expression is increased. Compared
to conventional methods of antibody production, GANP®Mouse Technology can
produce higher-affinity and higher-specificity antibodies with a higher success
rate. Therefore it is considered that the technology has many advantages in applying
it to development of diagnostic reagents and pharmaceuticals.
We regard it as a fundamental technology in our antibody-related technological
platforms and promote various businesses utilizing it. For example, we are developing
our original products, offering custom production services and granting its license
to pharmaceutical companies and diagnostic reagent manufacturers to gain profits
from its licensing fees and product royalties.
- What is GANP (Germinal Center Associated Nuclear Protein)?
It is a new nuclear factor increasingly expressed in germinal-center B cells.
Dr. Nobuo Sakaguchi of Kumamoto University discovered it.
- What are characteristics of GANP®mice?
Expression of GANP genes in germinal-center B cells is more increased in GANP
mice than in normal mice. These GANP proteins cause the genetic alteration
of the V regions with increased mutations. Therefore high-affinity and high-specificity
antibodies can be produced with a high success rate.
Sakaguchi N. et al., J Immunol. 2005 Apr 15;174(8):4485-94.
|
|
*2
|
AGEs (Advanced Glycation End Products)
It is a generic term for end products of protein glycation
reaction in vivo.
AGE-1 to 6, CML, CEL, Pentosidine, pyrraline,
imidazolone and crossline are some of the examples.
It has been suggested that formation and accumulation
of AGEs are closely linked to diabetes-related diseases
and chronic
disorders caused by aging.
We have been supporting researches
on AGEs by distributing AGEs-related antibodies listed
below.
| Code |
Product Name |
| KH001 |
Anti AGEs Monoclonal Antibody |
KH002
|
Anti AGEs Monoclonal Antibody, Fab' Peroxidase Conjugated |
| KH010 |
Anti Pyrraline Monoclonal Antibody |
| KH011 |
Anti CML Monoclonal Antibody |
| KH012 |
Anti Pentosidine Monoclonal Antibody |
| KH024 |
Anti CML Monoclonal Antibody |
| KH025 |
Anti CEL Monoclonal Antibody |
| KH039 |
Anti Human RAGE polyclonal antibody |
| KH040 |
Anti Human Galectin-3 polyclonal antibody |
| KH043 |
Anti 3-DG-imidazolone Monoclonal Antibody |
|
|
*3
|
AGE-3
It is a generic term for AGEs produced by reaction between
glycolaldehyde and protein. It is considered to be closely
linked to development and progression of various diseases
including diabetic complications (e.g. diabetic retinopathy
and nephropathy).
|
|
| |
| |
|
